Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease?
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- May 4, 2023
has subject area
- 1102 Cardiorespiratory Medicine and Haematology (FoR)
- 1117 Public Health and Health Services (FoR)
- Aspirin (MeSH)
- Cardiovascular Diseases (MeSH)
- Cardiovascular System & Hematology (Science Metrix)
- Clopidogrel (MeSH)
- Drug Therapy, Combination (MeSH)
- Humans (MeSH)
- Platelet Aggregation Inhibitors (MeSH)
- Purinergic P2Y Receptor Antagonists (MeSH)
- Receptors, Purinergic P2Y12 (MeSH)
- Secondary Prevention (MeSH)